Risk communication and the pharmaceutical industry: What is the reality?

Drug Safety

Volumn 35, Issue 11, 2012, Pages 1027-1040

  Edwards, Brian ^a   Chakraborty, Sweta ^b  

^a NDA Regulatory Science Ltd   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Labelling; Pharmaceutical Industry; Regulatory process; Risk communication.

Indexed keywords

ATORVASTATIN; BOTULINUM TOXIN A; FLUINDOSTATIN; LEXIPAFANT; MEFLOQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; COMPREHENSION; CONSUMER; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNET; LEGAL ASPECT; MEDICATION ERROR; PATIENT INFORMATION; PATIENT SAFETY; PERCEPTION; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RESPONSIBILITY; RISK BENEFIT ANALYSIS; RISK MANAGEMENT;

COMMUNICATION; CONSUMER HEALTH INFORMATION; DRUG INDUSTRY; DRUG TOXICITY; HEALTH PERSONNEL; HUMANS; LEGISLATION, DRUG; PAMPHLETS; PATIENT EDUCATION AS TOPIC; PATIENT MEDICATION KNOWLEDGE; PHARMACEUTICAL PREPARATIONS; PHARMACOVIGILANCE; RISK; RISK MANAGEMENT;

EID: 84867523031     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11635220-000000000-00000     Document Type: Article

References (62)

1. Slovic P, Peters E, Grana J, et al. Risk perception of prescription drugs: results of a national survey. Drug Inf J 2007; 41 (1): 81-100
2. US FDA. FDA alerts health care professionals of infection risk from repackaged Avastin intravitreal injections [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm270296.htm [Accessed 2012 Mar 30]
3. Fierce Healthcare. Hospitalizations for medication and illicit drug-related conditions on the rise among Americans ages 45 and older [online]. Available from URL: http://www.fiercehealthcare.com/press-releases/ hospitalizationsmedication-and-illicit-drug-related-conditions-rise- amongamericans-? utm-medium=nlutm-source=internal [Accessed 2012 Mar 25]
4. Lazar K. Nursing home drug use puts many at risk [online]. Available from URL: http://www.boston.com/news/health/articles/2010/03/08/antipsychotic-drug- use-for-dementia-patients-is-questioned/[Accessed 2012 Mar 25]
5. McCleery J. Antipsychotic prescribing in nursing homes. BMJ 2012; 344: 7
6. White JA. FDA finds problems with insulin pumps 'across manufacturers' [online]. Available from URL: http://blogs. wsj.com/health/2010/03/03/fda-finds- problems-with-insulinpumps-across-manufacturers/tab/print/[Accessed 2012 Mar 11]
7. Management of safety information from clinical trials. Report of CIOMS Working Group VI [online]. Available from URL: http://www.cioms.ch/publications/ blurbs/man agement-of-safety-information.htm [Accessed 2012 Jun 3]
8. SOMO briefing paper on ethics in clinical trials #1: examples of unethical trials February 2008 (updated) [online]. Available from URL: http://somo.nl/html/paginas/pdf/Ex amples-of-unethical-trials-nov-2006-NL.pdf [Accessed 2012 Mar 12]
9. Lehman R, Loder E. Missing clinical trial data. BMJ 2012; 314: 1-2
10. Perfetto EM, Ellison R, Ackermann S, et al. Evidence based risk management: how can we succeed? Deliberations from a Risk Management Advisory Council. Drug Inf J 2003; 37: 127-34
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: pharmacovigilance planning E2E [online]. Available from URL: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E2E/Step4/E2E-Guideline.pdf [Accessed 2012 Mar 25]
12. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003; 12 (1): 17-29
13. European Medicines Agency. Annex C: template for EU risk management plan (EU-RMP). Doc. Ref. EMEA/192632/2006 [online]. Available from URL: http://eudravigilance. ema.europa.eu/human/docs/19263206en.pdf [Accessed 2012 Mar 25]
14. Volume 9A of the rules governing medicinal products in the European Union guidelines on pharmacovigilance for medicinal products for human use [online]. Available from URL: http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a- 09-2008-en.pdf [Accessed 2012 Jun 3]
15. US Department of Health and Human Services, FDA. Guidance medication guides: distribution requirements and inclusion in risk evaluation and mitigation strategies (REMS). November 2011 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/ Guidances/UCM244570.pdf [Accessed 2012 Aug 23]
16. Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Risk Management Plan (RMP) guidance (Draft). August 2011 [online]. Available from URL: http://www.pmda.go.jp/english/service/pdf/mhlw/20110802-RMP. pdf [Accessed 2012 Aug 23]
17. Medicines and Healthcare products Regulatory Agency.Good pharmacovigilance practice guide. London: Pharmaceutical Press, 2009; 7: 89
18. Rayner DK. What is wrong with current SmPCs? DIA Product Information Forum. 2011 Jun 8; London 19.
19. Raynor DK Testing, testing ... user testing and how it will revolutionise how we think about patient information leaflets. Pipeline April 2005; 86: 4-5
20. MHRA. Report of the findings of the survey of user test houses undertaken on behalf of the Commission on Human Medicines Expert Advisory Group on Patient Information (CHMEAGPI) [online]. Available from URL: http://www.mhra.gov.uk/ home/groups/pl-a/documents/websiteresources/con2030408.pdf [Accessed 2012 Aug 23]
21. MHRA. Further guidance on designing patient information leaflets and how to achieve success in user testing. March 2007 [online]. Available from URL: http://www.mhra.gov. uk/home/groups/pl-a/documents/websiteresources/con2030 572.pdf [Accessed 2012 Aug 23]
22. Annex I: summary of product characteristics, and annex III: labelling and package leaflet. Version 8, 07/2011 Rev. 1, 10/2011 [online]. Available from URL: http://www.emea. europa.eu/docs/en-GB/document-library/Template-or-form/ 2009/10/WC500004368.pdf [Accessed 2012 Mar 30]
23. CMDh. Position paper on user testing of package leaflet: consultation with target patient groups (compliance with article 59(3) of council directive 2001/83/EC). Doc. Ref: CMDh/234/2011, February 2011 [online]. Available form URL: http://www.hma.eu/fileadmin/dateien/Human-Medicines/CMD-h-/procedural- guidance/Consulation-Patients Groups/CMDh-234-2011.pdf [Accessed 2012 Mar 11]
24. The Helen Hamlyn Research Centre. A guide to the graphic design of medication packaging. Second edition [online]. Available from URL: http://www.hhc.rca.ac.uk/cms/files/npsa-design-for-patient-safety-.pdf [Accessed 2012 Mar 11]
25. Harris E, Enright D. New words for cautionary and advisory labels make them easily understood. Pharm J 2011 Mar; 286: 278-9
26. EMA. Committee for Human Medicinal Products (CHMP). Guideline on the acceptability of names for human medicinal products processed through the centralised procedure CPMP/328/98 [online]. Available from URL: www.ema.europa.eu/pdfs/human/regaffair/032898en.pdf [Accessed 2012 Aug 23]
27. Institute for Safe Medication Practices. ISMP's list of confused drug names [online]. Available from URL: http://www.ismp. org/tools/ confuseddrugnames.pdf [Accessed 2012 Aug 23]
28. WHO, The Joint Commission. Look-alike, sound-alike medication names [online]. Available from URL: http://www.ccforpatientsafety.org/common/pdfs/ fpdf/Presskit/PS-Solution1.pdf [Accessed 2012 Aug 23]
29. Wilke T, Mueller S, Kai N, et al. Does package design matter for patients? The association between package design and patients' drug knowledge Pharm Med 2011; 25 (5): 307-17
30. Shrank W, Avorn J, Rolon C, et al. Effect of content and format of prescription drug labels on readability, understanding, and medication use: a systematic review. Ann Pharmacother 2007; 41 (5): 783-801
31. van Grootheest ACK, Edwards IR. Labeling and 'Dear Doctor'letters: are they noncommittal? Drug Saf 2002; 25 (15): 1051-5
32. Campbell WH, Califf RM. Improving communications of drug risks to prevent patient harm: proceedings of a workshop. Pharmacoepidemiol Drug Saf 2003; 12: 183-94
33. Goldman SA. Communication of medical product risk: how effective is effective enough? Drug Saf 2004; 27 (8): 519-34
34. Mazor KM, Andrade SE, Auger J, et al. Communicating safety information to physicians: an examination of Dear Doctor letters. PharmacoepidemiolDrug Saf 2005; 14: 869-75
35. Dusetzina S, Higashi A, Dorsey ER, et al. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review Med Care 2012; 50 (6): 466-78
36. Piening S, Haaijer-Ruskamp FM, de Vries JTN, et al. Impact of safety-related regulatory action on clinical practice: a systematic review. Drug Saf 2012; 35 (5): 373-85
37. Harris Interactive. The growing influence and use of health care information obtained online [online]. Available from URL: http://www. harrisinteractive.com/NewsRoom/Har risPolls/tabid/447/ctl/ReadCustom%20Default/ mid/1508/ArticleId/863/Default.aspx [Accessed 2012 Mar 26]
38. Acharya N, Hochstetler H. Healthcare provider focused communications. 9th Annual DIA Conference on Contemporary Pharmacovigilance and Risk Management Strategies. 2010 Jan 11-13; Washington, DC 39. ABPI. Pharmacovigilance and the internet: a call for change. A white paper from the ABPI Pharmacovigilance Expert Network, 13 June 2011 [online]. Available from URL: http://www.abpi.org. uk/our-work/library/industry/Pages/pharmacovigilance-the-internet.aspx [Accessed 2012 Aug 23]
39. Davis JJ, Cross E, Crowley J. Pharmaceutical websites and the communication of risk information. J Health Commun 2007; 12 (1): 29-39
40. Williams B, Brown D. Direct to consumer internet advertising of statins: an assessment of safety. Pharmacoepidemiol Drug Saf 2012; 21: 352-65
41. Salas M, Martin M, Pisu M, et al. Analysis of US Food and Drug Administration warning letters false promotional claims relating to prescription and over-the-counter medications. Pharm Med 2008; 22 (2): 119-25
42. NDA 20-553, OxyContin (oxycodone HCl controlledrelease) tablets, MACMIS ID# 11400. Released by FDA: 1/17/03. Posted by FDA: 1/22/03 [online]. Available from URL: http://www.pharmcast.com/WarningLetters/Yr2003/Jan2003/ PurduePharma0103.htm [Accessed 2012 Mar 11]
43. Gellad ZF, Lyles KW. Direct-to-Consumer Advertising of Pharmaceuticals. Am J Med 2007; 120: 475-80
44. Kalshera MJ, Wogalterb MS. Influence of presentation modality on communication of pharmaceutical risk information in direct-to-consumer (DTC) television commercials [online]. Available from URL: http://www. safetyhumanfactors. org/wp-content/uploads/2011/12/284KalsherWogalter2006. pdf [Accessed 2012 Mar 11]
45. Division of Drug Marketing, Advertising, and Communications, Office of Medical Policy, Center for Drug Evaluation and Research, Food and Drug Administration and Office of Planning, Office of the Commissioner, Food and Drug Administration and Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services. A supplementary test of distraction inDTC advertising using an implicit measure, the affect misattribution procedure. June, 2011 [online]. Available from URL: http://www.fda.gov/downloads/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/CDER/UCM285379. pdf [Accessed 2012 Mar 30]
46. Clinical Human Factors Group [online]. Available from URL: http://www.chfg.org [Accessed 2012 Jun 3]
47. Supreme Court of the United States. Wyeth v. Levine. No. 06-1249. Argued November 3, 2008-Decided March 4, 2009 [online]. Available from URL: http://www.law.cornell. edu/supct/html/06-1249.ZS.html [Accessed 2012 Mar 25]
48. Curtin T, Relkin E Preamble preemption and the challenged role of failure to warn and defective design pharmaceutical cases in revealing scientific fraud, marketing mischief, and conflicts of interest [online]. Available from URL: http://lawarchive.hofstra.edu/pdf/Academics/Journals/LawReview/lrv-issues- v35n04-CC4-CurtinRelkin-35-4-final.pdf [Accessed 2012 Mar 30]
49. Exchange censures British Biotech [online]. Available from URL: http://www.execreview.com/1999/06/exchange-censuresbritish-biotech/[Accessed 2012 Mar 11]
50. The United States Department of Justice, Office of Public Affairs. Allergan agrees to plead guilty and pay 600 million to resolve allegations of off-label promotion of Botox-. Wednesday, September 1, 2010 [online]. Available from URL: http://www.justice.gov/opa/pr/2010/September/10-civ-988.html [Accessed 2012 Mar 11]
51. Newman M. Bitter pills for pharma. BMJ 2010; 341: 632-3
52. Cohen D. Rosiglitazone: what went wrong. BMJ 2010; 341: 530-5
53. Largen S. Spartanburg judge upholds 327M verdict against pharmaceutical company [online]. Available from URL: http://www.goupstate.com/article/20111221/ ARTICLES/111229952/1051/news?Title=Spartanburg-judge-upholds-327M-verdict- against-pharmaceutical-company [Accessed 2012 Mar 11]
54. Brian D, Feder N. Joint advisory committee meeting on Yaz and Yasmin: industry ties. January 11, 2012 [online]. Available from URL: http://www.pogo.org/pogo-files/letters/public-health/ph-fda-20120111-pogo- letter-fda-advisors.html [Accessed 2012Mar 11]
55. European Public Health Alliance Direct-to-consumer communication by pharmaceutical companies? Europeans deserve better [online]. Available from URL: http://www.epha.org/a/3925 [Accessed 2012 Mar 11]
56. Davis JJ. Consumers' preferences for the communication of risk information in drug advertising. Health Aff (Millwood) 2007; 26 (3): 863-70
57. Lipkus IM. Numeric, Verbal and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Making 2007; 27: 696-713
58. Berkman ND, Sheridan SL, Donahue KE, et al. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med 2011; 155 (2): 97-107
59. van der Waarde K. Enabling users or readability? Graphic-Design Research May 2005; 1-12
60. Yin HS, Dreyer BP, van Schaick L, et al. Randomized controlled trial of a pictogram-based intervention to reduce liquid medication dosing errors and improve adherence among caregivers of young children. Arch Pediatr Adolesc Med 2008; 162 (9): 814-22
61. Edwards B, Olsen AK, Whalen MW, et al. Guiding principles of safety. Curr Drug Saf 2007; 2: 135-9
62. Hugman B. Healthcare Communication. London: Pharmaceutical Press, 2009 Apr